IBRX and the BCG Shortage: A 2026 Catalyst Investors Are Tracking

ImmunityBio IBRX is scaling a strategy that sits at the intersection of a persistent Bacillus Calmette-Guérin (BCG) shortage and expanding use of its lead immunotherapy, Anktiva. That combination is shaping unusual demand dynamics in non-muscle invasive bladder cancer (NMIBC).

For investors, 2026 brings a set of measurable checkpoints that can clarify pace and durability of adoption, as well as how quickly the company can extend its reach beyond the United States.

IBRX’s BCG Shortage Setup Creates Unusual Demand Dynamics

The BCG shortage is positioned as a structural catalyst because it is not a one-quarter issue. It is an ongoing supply imbalance that can reshape how community urology practices source and sequence therapy.

ImmunityBio is using the shortage backdrop to expand access pathways that keep urologists engaged, while also reinforcing Anktiva’s role in NMIBC. The company’s approach aims to deepen relationships in urology at the point where treatment decisions are made and repeated prescribing patterns can form.

ImmunityBio’s Expanded Access Program Is Scaling

The FDA-authorized expanded access program for recombinant BCG has scaled to roughly 100 active or activating sites and treated more than 500 patients by January 2026.

Operationally, “several thousand doses delivered” signals throughput that matters in a constrained supply environment. The program’s footprint in community settings can support broader urology engagement over time, creating an access channel that is distinct from standard commercial launch mechanics.

As that footprint grows, it can also improve longer-term visibility for combination use with Anktiva, since community sites gaining experience with recombinant BCG may be more prepared to integrate adjacent regimens as evidence and access expand.

ImmunityBio, Inc. Price and Consensus

ImmunityBio, Inc. price-consensus-chart | ImmunityBio, Inc. Quote

IBRX Has a Near-Term FDA Touchpoint in March 2026

A scheduled FDA meeting in March 2026 is set to address the regulatory pathway for the recombinant BCG program.

This is a definable 2026 catalyst because it can reduce uncertainty around the path forward and clarify what the agency expects next. The outcome can also reset timelines, depending on the direction provided, making it a key event investors can track without needing to assume an endpoint beyond what is already laid out.

ImmunityBio’s NMIBC Data Are the Demand Anchor

Demand ultimately rests on clinician confidence, and the company highlights NMIBC outcomes that support engagement. In BCG-unresponsive carcinoma in situ (with or without papillary tumors), Anktiva plus BCG achieved a complete response rate of 71%, with durability described as extending beyond 53 months and bladder preservation supported by 36-month data.

That blend of response, durability, and bladder preservation language helps explain why urologists may remain involved as access broadens. It ties the shortage-era effort to a therapy story that is anchored in outcomes rather than logistics alone.

The next potential addressable expansion highlighted is BCG-naïve NMIBC carcinoma in situ (with or without papillary tumors). Interim analysis showed higher 6- and 9-month complete response rates with Anktiva plus BCG, and the company is targeting an FDA filing before the end of 2026, with pivotal study data expected in the fourth quarter of 2026.

IBRX’s Global Launch Adds Another Layer to the Trend

International expansion can widen the commercial canvas as the company moves beyond a U.S.-led revenue base. In February 2026, the European Commission granted conditional marketing authorization for Anktiva plus BCG in the same BCG-unresponsive NMIBC indication already authorized in the United States.

The company’s European strategy is structured around country-by-country reimbursement, with the Big 5 prioritized and Germany expected to commercialize first in 2026 through Accord Healthcare’s deployment across 31 European countries.

Saudi Arabia adds another geographic node. The company cites Saudi approvals and readiness for shipments to commence, which can extend reach while the EU pathway unfolds through reimbursement sequencing.

ImmunityBio’s Execution and Scaling Tools Could Matter More in 2026–2027

Execution becomes more complex as programs and geographies multiply, and ImmunityBio is leaning on scaling tools aimed at de-risking that complexity. The NANT Leonardo AI-robotic platform is planned to automate natural killer cell and chimeric antigen receptor-natural killer cell production, with the intent of lowering costs and enabling continuous, auditable manufacturing.

Separately, the askIB AI initiative spans research and development, manufacturing, and operations to accelerate decision-making as scale increases. These efforts are framed as enablers for a 2026–2027 period that the company describes as an international ramp alongside continued U.S. penetration, even as execution complexity remains a key consideration.

Trend Risks Investors Should Not Ignore

Investors should keep the key risks in view: intense competition, dependence on Anktiva as the primary driver, and uncertainty around ex-U.S. revenue ramp timing tied to reimbursement sequencing and regional logistics.

Competition in urologic oncology extends beyond NMIBC supply dynamics. Larger oncology players like Merck MRK and Johnson & Johnson JNJ already have significant presence across bladder and urothelial cancer treatment settings, which can shape mindshare and standards of care as new options emerge.

The “trend” thesis ultimately ties back to measurable checkpoints already cited: sequential U.S. net product sales growth exiting the fourth quarter of 2025, EU launch progress and reimbursement wins, FDA interactions for recombinant BCG, and clinical and regulatory milestones heading toward the end of 2026.

IBRX’s Zacks Rank

ImmunityBio currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Just Released: Zacks Top 10 Stocks for 2026

Hurry – you can still get in early on our 10 top tickers for 2026. Handpicked by Zacks Director of Research Sheraz Mian, this portfolio has been stunningly and consistently successful.

From inception in 2012 through November, 2025, the Zacks Top 10 Stocks gained +2,530.8%, more than QUADRUPLING the S&P 500’s +570.3%.

Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2026. You can still be among the first to see these just-released stocks with enormous potential.

See New Top 10 Stocks >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Johnson & Johnson (JNJ): Free Stock Analysis Report

Merck & Co., Inc. (MRK): Free Stock Analysis Report

ImmunityBio, Inc. (IBRX): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research